Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
InnoCan Pharma Submits New Patent Applications for Advanced Pain Relief Technology
InnoCan Pharma, a pharmaceutical technology company leveraging its novel cannabis-based therapeutics portfolio of targeted healing […]
Modus Therapeutics Presented New Data on Anemia Treatment
Modus Therapeutics, a company developing innovative treatments for patients with major unmet medical needs, announces […]
Genezen Announces the Appointment of Key Executive Leaders, Expanding Viral Vector Capabilities
Genezen, a gene and cell therapy contract development and manufacturing organization (CDMO), today announced the […]
NIH Approves Second Phase of Funding to Support IND-enabling Work for Ambulero Gene Therapy to Treat Vascular Disease
Ambulero is developing a first-in-class gene and cell therapy platform for treating serious vascular diseases […]
Lantern Pharma Receives FDA Clearance of IND Application for Drug Candidate LP-184 in Solid Tumors
Lantern Pharma, an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary […]
BC Platforms Expands Data Partner Network with Major Brazilian Cardiovascular Health Institution
BC Platforms (BCP), a global leader in healthcare data management and analytics, today announces the […]
Charles River and Curigin Collaborate to Produce Oncolytic RNAi Gene Therapy
Charles River Laboratories International and Curigin, a Korean biotechnology company developing innovative oncolytic ribonucleic acid […]
SOMAÍ Pharmaceuticals Signs Supply Contract with Cosma Poland
SOMAÍ Pharmaceuticals has entered into a two-year supply agreement with a well-respected Polish distributor Cosma […]
FDA Advisory Committee Votes Unanimously to Confirm Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Early Alzheimer's Disease
BioArctic AB‘s partner Eisai announced that the US Food and Drug Administration’s (FDA) Peripheral and […]
Intellia Therapeutics Announces New Positive Clinical Data from Study of an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema
Intellia Therapeutics, a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more